Giulia Costa

Dr. Giulia Costa

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2024 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
ABAndrea Buono
Andrea Buono
AZAndrea Zito
Andrea Zito
WKWon-Keun Kim
Won-Keun Kim
TFTommaso Fabris
Tommaso Fabris
CBChiara De Biase
Chiara De Biase
GTGiuseppe Tarantini
Giuseppe Tarantini

1 July 2020 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
GCGiulia Costa
Giulia Costa
GBGintautas Bieliauskas
Gintautas Bieliauskas
MFMotoki Fukutomi
Motoki Fukutomi
NINikolaj Ihlemann
Nikolaj Ihlemann
LSLars Søndergaard
Lars Søndergaard
OBOle De Backer
Ole De Backer

24 January 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
RLRaffaele De Lucia
Raffaele De Lucia
CGCristina Giannini
Cristina Giannini
MPMatteo Parollo
Matteo Parollo
VBValentina Barletta
Valentina Barletta
GCGiulia Costa
Giulia Costa
APAnna Sonia Petronio
Anna Sonia Petronio
Permanent pacemaker implantation (PPM-I) remains nowadays the most important drawback of transcatheter aortic valve replacement (TAVR) procedure and the optimal strategy of delayed conduction disturbances (CDs) in these patients is unclear. The study aimed to validate an ambulatory electrocardiogram (ECG) monitoring through a 30 s spot ambulatory digital mobile ECG (AeECG), by using KardiaMobile-6L device in a 30-day period after TAVR procedure. Between March 2021 and February 2022, we consecutively enrolled all patients undergoing TAVR procedure, except pacemaker (PM) carriers. At discharge, all patients were provided of a KardiaMobile-6L device and a spot digital ECG (eECG) recording 1 month schedule. Clinical and follow-up data were collected, and eECG schedule compliance and recording quality were explored. Among 151 patients without pre-existing PM, 23 were excluded for pre-discharge PPM-I, 18 failed the KardiaMobile-6L training phase, and 10 refused the device. Delayed CDs with a Class I/IIa indication for PPM-I occurred in eight patients (median 6 days). Delayed PPM-I vs. non-delayed PPM-I patients were more likely to have longer PR and QRS intervals at discharge. PR interval at discharge was the only independent predictor for delayed PPM-I at multivariate analysis. The overall eECG schedule compliance was 96.5%. None clinical adverse events CDs related were documented using this new AeECG monitoring modality. A strategy of 30 s spot AeECG is safe and efficacious in delayed CDs monitoring after TAVR procedure with a very high eECG schedule level of compliance. (A) Flow chart programme for patient access to the device training phase and its rules. (B) eECG 1 month schedule. (C ) Histogram illustrating the number of cases and associated time to development of delayed CDs requiring PPM-I. CD, conduction disturbance; eECG, digital electrocardiogram; PPM-I, permanent pacemaker implantation.

3 July 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
YJYuheng Jia
Yuheng Jia
AMAnnette Maznyczka
Annette Maznyczka
MBMauro Boiago
Mauro Boiago
AKArif Azhar Khokhar
Arif Azhar Khokhar
DTDaijiro Tomii
Daijiro Tomii
OBOle De Backer
Ole De Backer
Background: Data concerning the long‐term durability of transcatheter aortic valves (TAVs) in patients with bicuspid aortic stenosis (AS) are lacking. Aims: The study aims to report data on long‐term valve durability following transcatheter aortic valve replacement (TAVR) in bicuspid AS. Methods: This multicentre registry included patients who underwent TAVR for bicuspid AS with at least 2‐year echocardiographic follow‐up. The incidence of structural valve deterioration (SVD), bioprosthetic valve dysfunction (BVD), and bioprosthetic valve failure (BVF) was determined according to Valve Academic Research Consortium (VARC)‐3 criteria. Results: Among 894 patients (mean age: 75.6 years; 39% female), the median echocardiographic follow‐up was 48.7 months with a 5‐year cumulative incidence of moderate‐to‐severe SVD, severe SVD, severe BVD, and BVF of 8.1%, 3.2%, 11.4%, and 6.1%, respectively. Younger age (≤ 75 years) was associated with a higher likelihood of reintervention (HR 2.40, log‐rank p = 0.04). TAV downsizing was associated with higher rates of moderate‐to‐severe SVD (HR 3.05, log‐rank p < 0.001), severe BVD (HR 2.07, log‐rank p = 0.003), and BVF (HR 3.25, log‐rank p = 0.002). In the sub‐group with small annuli (area ≤ 430 mm 2 ), implantation of balloon‐expandable TAVs was associated with a higher rate of BVD in comparison with self‐expanding TAVs (HR: 3.27, log‐rank p = 0.008). Conclusions: TAVs demonstrated favorable 5‐year durability in patients with bicuspid AS, although younger patients were more likely to require valve reintervention. Nominal TAV sizing was associated with better durability outcomes as compared to TAV downsizing. Self‐expanding valves were associated with superior hemodynamics in patients with small annuli.

28 April 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
Alessandro SticchiAlessandro Sticchi
Alessandro Sticchi
DGDario Grassini
Dario Grassini
GCGiulia Costa
Giulia Costa
PSPaolo Spontoni
Paolo Spontoni
MAMarco Angelillis
Marco Angelillis
MCMarco De Carlo
Marco De Carlo

28 November 2023 in The American Journal of Cardiology
Verified
Journal Article
Closed access
GCGiulia Costa
Giulia Costa
CGCristina Giannini
Cristina Giannini
MMMatteo Mazzola
Matteo Mazzola
MAMarco Angelillis
Marco Angelillis
CPChiara Primerano
Chiara Primerano
APAnna Sonia Petronio
Anna Sonia Petronio